MBIP Inhibitors
MBIP inhibitors are a diverse group of compounds that exert their inhibitory effects through various mechanisms within the cellular signaling network. These inhibitors often target key kinases within the MAPK signaling pathway, a central conduit for cellular responses to external stimuli that MBIP is associated with. For instance, inhibitors that focus on MEK proteins can disrupt the signaling cascade leading to MBIP, effectively reducing MBIP's functional activity. This is because MBIP's regulatory influence within the MAPK pathway is contingent upon the proper functioning and activation of these upstream kinases. Similarly, compounds that inhibit the activity of the p38 MAPK can indirectly lessen the regulatory role of MBIP by blocking an alternative MAPK pathway, potentially altering MBIP's interactions and regulatory functions.
Additionally, the inhibitory action of certain compounds on PI3K and mTORC1 pathways also has repercussions for MBIP's activity. By impeding upstream signals that may influence MAP3K12, with which MBIP interacts, the role of MBIP in modulating downstream effects is attenuated. Direct kinase inhibitors that target a broad spectrum of kinases, or specific kinases such as JNK, Src family kinases, or RAF, can also lead to the inhibition of MBIP by preventing the phosphorylation and activation of proteins that would otherwise engage MBIP in signaling. Furthermore, inhibitors that target protein kinase C (PKC) could also affect the MAPK pathway signaling and therefore, by extension, decrease MBIP's activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
This kinase inhibitor is known to block a wide range of protein kinases, thus potentially inhibiting the phosphorylation events required for MBIP activation and its associated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Acts as an inhibitor of JNK, which is involved in the MAPK signaling pathway. By inhibiting JNK, it can prevent the activation of downstream proteins that MBIP might regulate. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
This compound inhibits MEK1/2, key kinases in the MAPK pathway. Since MBIP is associated with this pathway, U0126 can indirectly lead to the inhibition of MBIP by preventing MEK-mediated signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a PI3K inhibitor, it impedes the PI3K/Akt pathway. Given that MBIP is a MAP3K12 binding protein, and MAP3K12 might be influenced by PI3K signaling, LY294002 can indirectly inhibit MBIP activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
This compound is a selective inhibitor of MEK, which blocks the MAPK/ERK pathway. By inhibiting MEK, PD98059 can indirectly prevent MBIP from exerting its effects within this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can indirectly inhibit MBIP by blocking the p38 MAPK signaling pathway, which may intersect with the pathways regulated by MBIP. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that, through inhibition of mTORC1, can have downstream effects on MAPK signaling pathways, potentially affecting MBIP's regulatory role. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
This is a potent PI3K inhibitor that can indirectly inhibit MBIP by disrupting upstream PI3K signaling that may modulate the MAPK pathway, to which MBIP is related. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
A multikinase inhibitor that targets RAF kinases, thereby potentially inhibiting MBIP through downstream effects on the MAPK pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
It is a Src kinase inhibitor that may indirectly inhibit MBIP by altering Src family kinase-mediated signaling pathways that can intersect with MAPK pathways. | ||||||